Collegium Pharmaceutical reported record net revenue of $129.6 million for Q4 2022, a substantial increase from $27.4 million in Q4 2021. The company's GAAP net loss was $(7.2) million, or $(0.21) loss per share, while non-GAAP adjusted net income was $42.2 million, or $1.09 adjusted earnings per share. They ended the quarter with a cash balance of $173.7 million.
Generated record quarterly net revenue of $129.6 million.
Achieved GAAP net loss of $(7.2) million, or $(0.21) loss per share.
Reported non-GAAP adjusted net income of $42.2 million, or $1.09 adjusted earnings per share.
Ended the quarter with a strong cash balance of $173.7 million.
Collegium Pharmaceutical reaffirms its full-year 2023 financial guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Analyze how earnings announcements historically affect stock price performance